Oncology
Xanthus Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML
Published in Medical Verdicts and Law Weekly, June 21st, 2007
Xanthus Pharmaceuticals, Inc. announced the presentation of initial results from the Company's Phase 2 study of Xanafide(R) in patients with secondary acute myeloid leukemia (AML). The presentation was made by Dr. Harry P. Erba, M.D., Ph.D., Associate Professor of Internal Medicine at the University of Michigan Health System, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). In the Phase 2 trial, treatment with Xanafide and ara-C was associated with a favorable complete remission rate and an acceptable safety profile.
"Patients with secondary AML have a very poor prognosis. Previous multi-center studies of patients with secondary AML...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
More Articles from Medical Verdicts and Law Weekly
- AARP New York
Long Island Seniors Rally for Rx Affordable Prescription Drugs and Cell Phone Protections - American Medical Informatics Association
AMIA and AHIMA Applaud House Passage of H.R. 1467, the '10,000 Trained by 2010 Act' - American Nurses Association
ANA and NYSNA Condemn Exploitation of Filipino Registered Nurses - Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $75 Million of Convertible Senior Notes - Aneurysm
Rudy Boesch: Still Living Life to the Fullest as a ``Survivor'' in More Ways Than One - ArQule, Inc.
ArQule Announces Offering of Common Stock - More from this issue of Medical Verdicts and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
